Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.1-SNAPSHOT built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions
Generated Narrative: Observation TxImp01
Related artifact: No display for RelatedArtifact (type: citation; url: https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19))
status: Final
category: Laboratory, Genetics
code: Therapeutic Implication
subject: Adam B. Everyman Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, ))
effective: 2019-04-01
performer: Organization some lab
derivedFrom: Observation Genotype display name
component
code: Medication assessed [ID]
value: clopidogrel
component
code: Therapeutic Implication
value: Poor metabolizer
component
code: Conclusion Text
value: For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/